Phenotypic Profiling for Improving Drug Discovery Productivity

Presented At:
LabRoots' Lab Automation Virtual Event 2018

Presented By:
Ellen Berg, PhD - Chief Scientific Officer, Translational Biology, Eurofins DiscoverX

Speaker Biography:
Dr. Ellen L. Berg is Chief Scientific Officer for the DiscoverX BioSeek Business Unit. Dr. Berg is responsible for the BioMAP® platform of human primary cell-based assays and predictive analysis tools. Dr. Berg was a founder and the CSO of BioSeek, acquired by DiscoverX in 2012, and previously led a research team at Protein Design Labs developing novel therapeutic antibodies for inflammatory diseases. She is an expert in in vitro models of human disease and tissue biology, holds a number of patents, and has authored over 75 publications in the areas of inflammation, systems biology, phenotypic drug discovery, and drug and toxicity mechanisms of action. Dr. Berg has served in various positions with the Society of Laboratory Automation and Screening and is a member of the Society of Toxicology. Dr. Berg has a Ph.D. from Northwestern University and was a Postdoctoral Fellow at Stanford University.

Webinar:
Phenotypic Profiling for Improving Drug Discovery Productivity

Webinar Abstract:
The pharmaceutical industry’s productivity crisis is well known with 90% of drug candidates failing in clinical testing, primarily due to unexpected toxicity or lack of efficacy. Despite advances in high throughput ‘omics technologies and the large volume of information that is now amassed on new drug candidates, the probability of success for new molecules is not improving. Scannel and Bosney (2016) have pointed to a lack of predictive preclinical models as one of the key factors. New approaches using human-based in vitro cell systems are showing promise for replacing the use of animal models, particularly in cases where animal testing has failed to predict human effects. These new approaches will be described along with case studies that illustrate how these methods can generate mechanistic hypotheses for drug induced cardiovascular toxicity. Also to be discussed is how phenotypic assay data may be incorporated into safety risk assessments through the adverse outcome pathway framework being developed for chemical safety testing.

Learning Objectives:
1. Learn about non-animal based in vitro assays for preclinical testing in drug discovery.
2. Review some of the factors that make it challenging to predict drug efficacy in clinical testing.
3. Find out about new hypotheses underlying cardiovascular disease and drug induced cardiotoxicity.

Earn PACE/CME Credits:
1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/virtual-event/lab-automation-2018)
2. Watch the webinar on YouTube above or on the LabRoots Website (https://www.labroots.com/virtual-event/lab-automation-2018)
3. Click Here to get your PACE (Expiration date – May 30, 2020 06:00 AM)– https://www.labroots.com/credit/pace-credits/2896/third-party

LabRoots on Social:
Facebook: https://www.facebook.com/LabRootsInc
Twitter: https://twitter.com/LabRoots
LinkedIn: https://www.linkedin.com/company/labroots
Instagram: https://www.instagram.com/labrootsinc
Pinterest: https://www.pinterest.com/labroots/
SnapChat: labroots_inc

Тэги:

#Phenotypic_Profiling_for_Improving_Drug_Discovery_Productivity #Earn_PACE/CME_Credits #cardiotoxicity #LabRoots'_Lab_Automation_Virtual_Event #Scannel_and_Bosney

Скачать видео